Infectious Laryngotracheitis (ILT) is an economically relevant upper-respiratory disease of chickens caused by an alphaherpesvirus taxonomically identified as Gallid herpesvirus 1 (GaHV-1) also known as ILTV. In densely populated poultry areas in which ILT is present, the disease is controlled by biosecurity and vaccination. Currently, two kinds of commercially available vaccines are being used for ILTV control, live-modified vaccines (Chicken Embryo Origin [CEO], and Tissue Culture Origin [TCO]) and ILT recombinant vaccines (Herpes Virus of Turkey-LT [HVT-LT] and Fowlpox-LT [FPV-LT]). Furthermore, the spread of ILTV to non-enzootic areas has encouraged the manufacture and license of oil-based inactivated ILTV vaccines in zones where the use of live-modified vaccines is prohibited and only the use of recombinant vaccines is allowed. The present work evaluated the protection conferred by these three types of vaccines, individually and in combination, in layers challenged with a virulent ILTV strain; established a serological baseline for the implementation of ELISA in surveillance programs; and attenuated a virulent strain of ILTV in cell culture for future vaccine development.